In News

Follow this topic

Bookmark

Record learning outcomes

The Medicines and Healthcare products Regulatory Agency (MHRA) has limited the use of nasal decongestant sprays containing xylometazoline and oxymetazoline to a maximum of 5 days, in line with advice from Expert Advisory Groups to the Commission on Human Medicines due to adverse  effects following prolonged use.

Excessive use of nasal sprays and drops containing xylometazoline and oxymetazoline can cause rebound congestion (a temporary swelling inside the nose that can lead to a chronic condition called rhinitis medicamentosa) which causes severe nasal congestion and damage to tissues.

All new packaging and leaflets will state the duration of use is not to exceed 5 days, and the wording of the leaflets will also be strengthened to emphasise the risks associated with prolonged use.

Professor Amira Guirguis, chief scientist at the Royal College of Pharmacy, said: “The Royal College of Pharmacy welcomes this update on the safe use of nasal decongestants containing xylometazoline and oxymetazoline.

“We support clearer product information and improved packaging, alongside consistent public messaging, to improve awareness that these products are for short-term use only and to avoid preventable harm. Pharmacists play a key role in supporting patients to use them safely and advising on safer alternatives where appropriate.”